Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis

Corrias MV, Parodi S, Tchirkov A, Lammens T, Vicha A, Pasqualini C, Träger C, Yáñez Y, Dallorso S, Varesio L, Luksch R, Laureys G, Valteau-Couanet D, Canete A, Pöetschger U, Ladenstein R, Burchill SA.

Pediatr Blood Cancer. 2018 Jul;65(7):e27052. doi: 10.1002/pbc.27052. Epub 2018 Mar 30. PMID: 29603574.

Previous
Previous

High-risk neuroblastoma treatment strategy: The experience of the SIOPEN group

Next
Next

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study